Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use of ICIs in combination with other forms of cancer t...
Main Authors: | Sean Khozin, Osama Rahma, Meghan E Sise, Shaily Arora, Ravikumar Komandur Elayavilli, Aakanksha Khandelwal, Mace Rothenberg, Laura Petrillo, Alexandra-Chloe Villani |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/7/e002896.full |
Similar Items
-
Management of the Adverse Effects of Immune Checkpoint Inhibitors
by: Manuel Morgado, et al.
Published: (2020-10-01) -
Ocular adverse events with immune checkpoint inhibitors
by: Tony Fang, et al.
Published: (2019-09-01) -
IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01) -
Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01) -
Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Cui TM, et al.
Published: (2020-11-01)